论文部分内容阅读
混合菌苗（ＭＢｖ）是由化脓性链球菌和沙雷氏菌灭活制备的一种免疫调变剂。研究结果表明：（１）ＭＢＶ能明显延长腹水型肝癌小鼠的存活期（对照组１６．７±１．０ｄ，治疗组：腹腔应用者１８．５±１．０ｄ皮下应用者１８．８±１．５ｄ，Ｐ＜０．０５）和明显抑制皮下肝癌瘤块的生长（对照组２．３１０．７ｇ，治疗组：腹腔应用者１．９±０．２ｇ，皮下应用者１；７ｔ０．３ｇ，Ｐ＜０．０１）；（２）ＭＢＶ皮下应用后可明显提高肿瘤单个核细胞的浸润程度（对照组４１．５±８．６个／高倍键视野，治疗组：皮下应用者７４．３±１１。９个／高倍镜视野，Ｐ＜０．０ｌ），而腹腔应用却无此现象；（３）腹腔应用或皮下应用ＭＢＶ后，荷瘤小鼠的脾脏均明显增大（对照组０；２７±０．０５ｇ治疗组：皮下应用者０．３７±０．０５ｇ，腹腔应用者０．３５±０．０５ｇ，Ｐ＜０．０５）。上述观察提示，ＭＢＶ是一种有效的免疫刺激剂。
Blended vaccine (MBv) is an immunomodulatory agent prepared by inactivation of Streptococcus pyogenes and Serratia marcescens. The results showed that: (1) MBV significantly prolonged the survival of mice with ascites hepatoma (16.7 ± 1.0d in control group, 18.8 ± in subcutaneous group in 18.5 ± 1.0d group 1.5d, P <0.05) and significantly inhibited the growth of subcutaneous hepatocellular carcinoma (control group 2.310.7g, treatment group: abdominal application of 1.9 ± 0.2g, subcutaneous application of 1; 7t0.3g , P <0.01). (2) Subcutaneous administration of MBV could significantly improve the infiltration of tumor mononuclear cells (41.5 ± 8.6 in the control group / high magnification key field, the treatment group: subcutaneous 74.3 ± 11.9 eyes / high magnification, P <0.01), but not in abdominal cavity. (3) After intraperitoneal or subcutaneous administration of MBV, the spleen of tumor-bearing mice were significantly increased (control group 0 ; 27 ± 0.05g treatment group: 0.37 ± 0.05g for subcutaneous users, 0.35 ± 0.05g for intraperitoneal users, P <0.05). The above observations suggest that MBV is a potent immunostimulant.